StemVax

21/05/2024

https://novaccessglobal.com/wp-content/uploads/2024/05/5_21_24-NovAccess-Global-Cedars-IDH1-Patent-Press-Release.pdf

30/04/2024

https://novaccessglobal.com/wp-content/uploads/2024/04/4_30_24-NovAccess-Global-Announces-New-License-to-Advance-its-Immunotherapy-Platform.pdf

14/03/2024

The 21st Annual World Congress of the Society for Brain Mapping & Therapeutics (SBMT) 2024 begins TODAY, Thursday, March 14th.
Our very own Dr. Christopher Wheeler presents today at 8:30 – 8:45 AM
S*x-Disparate Neurodevelopmental Pathology and Decreased Cognitive Decline in Mice Lacking a Resident-Memory T Cell Gene
- Dr. Christopher Wheeler,
Senior Research Scientist SBMT; T-Neuro Pharma; StemVax

The 21st Annual World Congress of the Society for Brain Mapping & Therapeutics (SBMT) 2024 begins TODAY, Thursday, March 14th.

The "Critical Advances in " Program will have fantastic presentations and discussions over the next four days. It is VERY EXCITNG!

This morning, I will be Chairing the session "S*x And Gender Differences And The Immune System" beginning at 8AM (PDT).

Please JOIN US in Room 409 B at the Los Angeles Convention Center, Concourse Hall, Second Floor and ENJOY this GREAT LINE-UP of Topics and Speakers!

8:00 – 8:15 AM
Behavioral Metrics and Subjective Cognitive Concerns Over the Lifespan for Males, Females - Dr. James Clifford, College of San Mateo

8:15 – 8:30 AM
S*x Differences in Pathology, Autoimmunity, and Behavior in the 3xTg-AD Mouse - Dr. Margaret Fahnestock, McMaster University

8:30 – 8:45 AM
S*x-Disparate Neurodevelopmental Pathology and Decreased Cognitive Decline in Mice Lacking a Resident-Memory T Cell Gene
- Dr. Christopher Wheeler,
Senior Research Scientist SBMT; T-Neuro Pharma; StemVax

8:45- 9:15 AM
Role of Immune T-regulatory Cells in Alzheimer’s Disease
Dr. Giulio Maria Pasinetti – Featured Speaker
Icahn School of Medicine at Mount Sinai; James J. Peters VA Medical Center (Bronx, NY) U.S. Department of Veterans Affairs

Finally, at 9:15 Am, this session closes with a Q & A

I hope to see you there! - Dr. Giulio Maria Pasinetti

Learn More about SBMT and our program
https://www.worldbrainmapping.org/home/annual-congress/programschedule/critical-advances-in-alzheimers-disease/

The Mount Sinai Hospital Graduate School of Biomedical Sciences at the Icahn School of Medicine

04/03/2024

https://novaccessglobal.com/wp-content/uploads/2024/03/3_1_24-NovAccess-Global-Provides-Business-Updates-and-Announces-Scheduling-of-Annual-Meeting-of-Shareholders.pdf

02/01/2024

NovAccess Global Announces $10.7 Million Financing

04/12/2023

NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
https://novaccessglobal.com/wp-content/uploads/2023/12/NovAccess-Global-Inc.-December-7th-PR-.pdf

04/10/2023

The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.

06/09/2023

US scientists suggest that anti-angiogenesis drugs could improve the function and delivery of CAR-T cell therapy.

21/08/2023

Glioblastoma is a virtually incurable brain cancer with a five-year-survival rate of only 10%. “It’s heartbreaking to keep telling people in clinic that we don’t have a cure,” said Jana Portnow, M.D., co-director of City of Hope’s Brain Tumor Program. “This is a tough tumor, and these pa...

09/08/2023

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.

27/07/2023

NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform


https://novaccessglobal.com/wp-content/uploads/2023/07/7_27_23-NovAccess-Global-XSNX-BCN-Partnership.pdf

21/07/2023

Dr. Dwain Irvin, NovAccess Global's CEO, explores the groundbreaking immunotherapy technology being used to combat glioblastoma. This technology is creating ...

19/07/2023

Dr. Dwain Irvin, CEO of NovAccess Global, unveils groundbreaking results from recent human trials and animal studies involving their 1st and 3rd generation t...

13/07/2023

NovAccess Global to Participate in National Brain Tumor Society’s Annual Glioblastoma Awareness Day
https://novaccessglobal.com/wp-content/uploads/2023/07/7_13_23-NovAccess-Global-to-Participate-in-Glioblastoma-Awareness-Day.pdf

16/06/2023

NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division


https://novaccessglobal.com/wp-content/uploads/2023/06/6_16_23-XSNX-and-CKN.pdf

05/06/2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

01/06/2023

https://novaccessglobal.com/wp-content/uploads/2023/06/6_1_23-NovAccess-Global-Big-Data-Strategy.pdf

31/05/2023

We're excited to share that NovAccess Global's Lead Scientist, Dr. Christopher Wheeler, PhD, and CEO, Dr. Dwain Irvin, PhD, attended the prestigious World Orphan Drug Congress in Washington, D.C., where Dr. Irvin presented groundbreaking research on XSNX immunotherapy candidate TLR-AD1 for brain tumor patients. Their work together on this novel immunotherapy began 18 years ago, and its recent Orphan Drug Designation is a monumental milestone, providing a wealth of benefits and opportunities; allowing rapid acceleration toward potential marketability. We're humbled by the opportunity to help brain tumor patients achieve significantly improved outcomes. Don't forget to follow us to stay up-to-date on this incredible journey!